| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
|
| | AM 5262 Basic information |
| Product Name: | AM 5262 | | Synonyms: | AM 5262;XPLWBHWPOUEOSJ-GSZYCOFVSA-N;Spiro[cyclopropane-1,1'-[1H]indene]-2-carboxylic acid, 6'-[[2-[(1R)-2,2-dimethylcyclopentyl]-2'-fluoro-5'-methoxy[1,1'-biphenyl]-4-yl]methoxy]-2',3'-dihydro-, (1R,2R)- | | CAS: | 1222088-90-5 | | MF: | C33H35FO4 | | MW: | 514.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1222088-90-5.mol |  |
| | AM 5262 Chemical Properties |
| Boiling point | 657.7±55.0 °C(Predicted) | | density | 1.26±0.1 g/cm3(Predicted) | | pka | 4.71±0.20(Predicted) |
| | AM 5262 Usage And Synthesis |
| Description | AM-5262 is a Potent GPR40 Full Agonist with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638. GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. | | Uses | AM-5262 is a GPR40 full agonist with an EC50 value of 0.081 μM. AM-5262 can be used for the research of type II diabetes[1]. | | in vivo | AM-5262 (26) (i.v., 0.5 mg/kg; oral, 2 mg/kg) improves rat PK profile and general selectivity profile[1].
AM-5262 (0-100 μM) enhances glucose stimulated insulin secretion (mouse and human islets) and improves glucose homeostasis in vivo (OGTT in HF/STZ mice) [1]. | | References | [1] Wang Y, et al. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles. ACS Med Chem Lett. 2013;4(6):551-555. Published 2013 May 7. DOI:10.1021/ml300427u |
| | AM 5262 Preparation Products And Raw materials |
|